Openbookopenbook
Equity
Dr. Reddy’s Laboratories Ltd ADR(RDY)
USD --+0.00%
Reward59Moderate
Risk22Low
📊75%Data
Strong 16% profit margin
RDY
+0.0 · +0.00%
USD · NYSE
Dr. Reddy’s Laboratories Ltd ADR | Healthcare
Defensive Anchor
Market Cap:11.97Bn
ℹ️
Reward Rating
59
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
22
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RDY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: ₹14.41.

What is Dr. Reddy’s Laboratories Ltd ADR?

Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

RDY · Verdict

Solid reward · low risk

RDY scores well on volatility and profitability with no major weaknesses flagged in the model.

Based on 88% data coverage

RDY · Verdict

What’s working & what to watch

Strengths 4

  • Volatility95/100

    Top decile vs peers

  • Profitability72/100

    17% net margin · 16% ROE

  • Balance sheet71/100

    Interest covered 28.1×

  • Cash flow70/100

    4% free-cash-flow margin

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Dr. Reddy’s Laboratories Ltd ADR?

Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 11.97B, and a P/E ratio of 19.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap11.97B
P/E Ratio19.1733
Dividend Yield0.64%
52 Week High16.0694
52 Week Low12.1837
Last AnnualMarch
IPO Date4/11/2001
IncorporatedUSA
Shares Outstanding833M
No. of Employees27,811
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNYSE
Beta0.294
CurrencyUSD · Reports in INR
Websitewww.drreddys.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.